Press Releases

09.03.2015

Pfizer Inc. Commences Exchange Offers for Hospira Notes

08.26.2015

Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer

08.24.2015

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015

08.24.2015

Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition

08.21.2015

Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA® (Meningococcal Group B Vaccine)

08.20.2015

Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer

08.14.2015

Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition

08.13.2015

HiFiBiO SAS Achieves Milestone in Antibody Research Collaboration with Pfizer Inc.

08.13.2015

Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisition of Hospira

08.04.2015

Pfizer Receives Approval From European Commission For Pending Acquisition Of Hospira

08.03.2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

07.28.2015

PFIZER REPORTS SECOND-QUARTER 2015 RESULTS